For research use only. Not for therapeutic Use.
TLR9-IN-1 is a potent and selective TLR9 inhibitor with an IC50 value of 7 nM for human TLR9. TLR9-IN-1 can be used for researching diseases associated with undesirable immune response[1].
TLR9-IN-1 (compound no.29) (0-10 μM; 24 h) exhibits moderately inhibitory activity against IL-1b with an IC50 of 1.61 μM in human monocytes (co-incubated with TLR8 agonist ORN8L, RNA oligonucleotide)[1].
| Catalog Number | I042910 |
| CAS Number | 2226366-86-3 |
| Synonyms | N-[3-(dimethylamino)propyl]-1-[2-(4-methylphenyl)pyrazolo[3,4-d]pyridazin-7-yl]piperidine-4-carboxamide |
| Molecular Formula | C23H31N7O |
| Purity | ≥95% |
| InChI | InChI=1S/C23H31N7O/c1-17-5-7-20(8-6-17)30-16-19-15-25-26-22(21(19)27-30)29-13-9-18(10-14-29)23(31)24-11-4-12-28(2)3/h5-8,15-16,18H,4,9-14H2,1-3H3,(H,24,31) |
| InChIKey | FRMXKWKQIYLSMO-UHFFFAOYSA-N |
| SMILES | CC1=CC=C(C=C1)N2C=C3C=NN=C(C3=N2)N4CCC(CC4)C(=O)NCCCN(C)C |
| Reference | [1]. Albert Frederick Candia, et al. Toll-like receptor antagonist compounds and methods of use. WO2018089695 |
